Patrick A Baeuerle
Overview
Explore the profile of Patrick A Baeuerle including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
98
Citations
5835
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sauer K, Rakhra K, Wu K, Mehta N, Michaelson J, Baeuerle P
Front Oncol
. 2024 Sep;
14:1456658.
PMID: 39252938
As powerful activators of the immune system, cytokines have been extensively explored for treating various cancers. But despite encouraging advances and some drug approvals, the broad adoption of cytokine therapies...
2.
Mehta N, Rakhra K, Meetze K, Li B, Momin N, Chang J, et al.
Cancer Immunol Res
. 2024 Jun;
12(8):1022-1038.
PMID: 38842347
Despite clinical evidence of antitumor activity, the development of cytokine therapies has been hampered by a narrow therapeutic window and limited response rates. Two cytokines of high interest for clinical...
3.
Michaelson J, Baeuerle P
J Exp Med
. 2024 Apr;
221(5).
PMID: 38587494
Jennifer S. Michaelson, Chief Scientific Officer at Cullinan Oncology, and Patrick A. Baeuerle, scientific advisor to Cullinan Oncology and honorary professor in immunology at Ludwig Maximilians University Munich, discuss the...
4.
McCarthy D, Lofgren M, Watt A, Horton H, Kieffer-Kwon P, Ding J, et al.
Cancer Immunol Immunother
. 2023 Oct;
72(12):4195-4207.
PMID: 37848682
T cells expressing a mesothelin (MSLN)-specific T cell receptor fusion construct (TRuC), called TC-210, have demonstrated robust antitumor activity in preclinical models of mesothelioma, ovarian cancer, and lung cancer. However,...
5.
Meetze K, Mehta N, Li B, Michaelson J, Baeuerle P
J Immunother Cancer
. 2023 Aug;
11(8).
PMID: 37586770
Background: Despite significant progress in the development of T cell-engaging therapies for various B-cell malignancies, a high medical need remains for the refractory disease setting, often characterized by suboptimal target...
6.
Whalen K, Rakhra K, Mehta N, Steinle A, Michaelson J, Baeuerle P
MAbs
. 2023 May;
15(1):2208697.
PMID: 37165468
The field of immuno-oncology has revolutionized cancer patient care and improved survival and quality of life for patients. Much of the focus in the field has been on exploiting the...
7.
Ding J, Guyette S, Schrand B, Geirut J, Horton H, Guo G, et al.
Oncoimmunology
. 2023 Mar;
12(1):2182058.
PMID: 36875551
T cell Receptor (TCR) Fusion Construct (TRuC®) T cells harness all signaling subunits of the TCR to activate T cells and eliminate tumor cells, with minimal release of cytokines. While...
8.
Baeuerle P, Wesche H
Curr Opin Oncol
. 2022 Jul;
34(5):552-558.
PMID: 35880455
Purpose Of Review: T-cell-engaging antibodies or T-cell engagers (TCEs) can connect a patient's cytotoxic T cells with cancer cells, leading to potent redirected lysis. Until very recently, only one TCE...
9.
Mehta N, Pfluegler M, Meetze K, Li B, Sindel I, Vogt F, et al.
J Immunother Cancer
. 2022 Mar;
10(3).
PMID: 35288466
Background: In lymphoid malignancies, the introduction of chimeric antigen receptor T (CAR-T) cells and bispecific antibodies (bsAbs) has achieved remarkable clinical success. However, such immunotherapeutic strategies are not yet established...
10.
Molloy M, Austin R, Lemon B, Aaron W, Ganti V, Jones A, et al.
Clin Cancer Res
. 2020 Dec;
27(5):1452-1462.
PMID: 33262134
Purpose: Mesothelin (MSLN) is a glycophosphatidylinositol-linked tumor antigen overexpressed in a variety of malignancies, including ovarian, pancreatic, lung, and triple-negative breast cancer. Early signs of clinical efficacy with MSLN-targeting agents...